IPXX,Inflection Point Acquisition Corp. II | Financials

Financials

IPXX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Inflection Point Acquisition Corp. IIIPXX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

91.19M

Revenue (ttm)

n/a

Net Income (ttm)

11.89M

Shares Out

8.46M

EPS (ttm)

0.37

PE Ratio

28.87

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

36,519

Open

11.45

Previous Close

10.98

Day's Range

9.24 - 11.50

52-Week Range

9.24 - 15.25

Beta

n/a

Analysts

n/a

Price Target

n/a

Earnings Date

n/a

Description >

Inflection Point Acquisition Corp. II does not have significant operations.

It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

The company was incorporated in 2023 and is based in New York, New York. Inflection Point Acquisition Corp. II operates as a subsidiary of Inflection Point Holdings II LLC.

Latest News >

India vs South Africa 2nd Test, Day 3: SA reaches 118 for 2 in chase of 240

Jan 5, 2022

India vs South Africa 2nd Test: India removed opener Aiden Markaram (34) and Keegan Petersen (28) but the home batters ensured there were no more setbacks after that. Earlier, resuming at 85 for two, India put on board 266 runs.

US CDC recommends Pfizer booster for 12- to 15-year-olds amid Omicron surge

Jan 6, 2022

Boosters already are recommended for everyone 16 and older, and federal regulators have decided they're also warranted for 12- to 15-year-olds once enough time has passed since their last dose.

The Medicine Box: India can become leader of innovative drugs, funding huge challenge, says Dr Reddy’s GV Prasad

Jan 6, 2022

The Medicine Box Podcast: In this edition, CNBC-TV18’s Ekta Batra gets in conversation with Dr Reddy’s Laboratories’ co-chairman and MD, GV Prasad, to discuss India’s potential to become a leader in making innovative drugs, the growth so far, and the associated challenges.

Opening Bell: Sensex, Nifty open sharply lower amid weak global cues; Airtel, Sun Pharma rise

Jan 6, 2022

The Indian equity benchmark indices opened sharply lower on Thursday with Nifty50 down 1 percent. There were not many gainers on the index this morning, the top ones are Hindalco, Sun Pharma, Cipla, DRL, and Airtel.